# EGFR in colorectal cancer

3 EU-approved indications in colorectal cancer need a EGFR result: cetuximab (metastatic), cetuximab (1st line, metastatic) and cetuximab (3rd line+, metastatic).

## Approved indications

### EGFR

| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| [Cetuximab](https://oncolabels.com/drugs/cetuximab) (Erbitux) | RAS wild-type, EGFR-expressing | + FOLFOX | 1st line, metastatic | - |
| [Cetuximab](https://oncolabels.com/drugs/cetuximab) (Erbitux) | RAS wild-type, EGFR-expressing | Monotherapy | 3rd line+, metastatic | Failed oxaliplatin- and irinotecan-based therapy; Intolerant to irinotecan Ambiguous in the label (line of therapy): check the SmPC. |
| [Cetuximab](https://oncolabels.com/drugs/cetuximab) (Erbitux) | RAS wild-type, EGFR-expressing | + irinotecan-based chemotherapy | Metastatic | - |

## Label wording

- **Cetuximab** (Erbitux), Colorectal cancer, metastatic: “Erbitux is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer
• in combination with irinotecan-based chemotherapy,” [SmPC](https://www.ema.europa.eu/en/documents/product-information/erbitux-epar-product-information_en.pdf)
- **Cetuximab** (Erbitux), Colorectal cancer, 1st line, metastatic: “Erbitux is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer
• in combination with irinotecan-based chemotherapy,
• in first-line in combination with FOLFOX,” [SmPC](https://www.ema.europa.eu/en/documents/product-information/erbitux-epar-product-information_en.pdf)
- **Cetuximab** (Erbitux), Colorectal cancer, 3rd line+, metastatic: “Erbitux is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer
• in combination with irinotecan-based chemotherapy,
• in first-line in combination with FOLFOX,
• as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/erbitux-epar-product-information_en.pdf)

Source: section 4.1 of each summary of product characteristics (SmPC), EMA data as of 5 Nov 2026. AI models structured these entries and no person has checked them yet. oncolabels is a non-commercial reference for education and research and gives no medical advice; the current SmPC takes precedence.

Data under CC BY 4.0: credit oncolabels and the European Medicines Agency. Page: https://oncolabels.com/tumours/colorectal-cancer/egfr